Assuntos
Síndrome de Down , Hemocromatose , Transplante de Fígado , Doadores Vivos , Humanos , Hemocromatose/complicações , Síndrome de Down/complicações , Recém-Nascido , Reação Leucemoide/patologia , Reação Leucemoide/genética , Masculino , Feminino , Síndrome Congênita de Insuficiência da Medula ÓsseaRESUMO
This case series investigates a cluster of deaths in a captive colony of Leschenault's rousettes (Rousettus leschenaultii). Six of seven bats that died between March and September 2021 were diagnosed postmortem with both iron overload (IO) and neoplasia, neither of which have previously been reported in this species. Iron status was assessed via hepatic histopathological grading, hepatic iron concentration, and, in two cases, serum iron concentration. On histopathological grading, all cases had hemochromatosis except one, which had hemosiderosis. Hepatic iron concentrations did not correlate with histopathological grading. Neoplasms in these six bats included hepatocellular carcinoma (HCC; 4), bronchioloalveolar adenocarcinoma (1), pancreatic adenocarcinoma (1), and sarcoma of the spleen and stomach (1). One bat had two neoplasms (HCC and sarcoma of the spleen and stomach). One additional case of HCC in 2018 was identified on retrospective case review. Etiology was investigated to the extent possible in a clinical setting. Nutritional analysis and drinking water testing found oral iron intake within acceptable bounds; however, dietary vitamin C was potentially excessive and may have contributed to IO. Panhepadnavirus PCR testing of liver tissue was negative for all bats. A species-associated susceptibility to IO, as seen in Egyptian fruit bats (Rousettus aegyptiacus), is possible. The high incidence of HCC is suspected to be related to IO; other differentials include viral infection. Causes or contributing factors were not definitively identified for the other neoplasms seen but could include age, inherited risk (given a high level of inbreeding), or an oncogenic virus. Pending further research in this species, it is recommended that keepers of Leschenault's rousettes offer conservative amounts of vitamin C and iron (as for Egyptian fruit bats), submit for postmortem examination any euthanized or found dead, and share records of similar cases.
Assuntos
Adenocarcinoma , Carcinoma Hepatocelular , Quirópteros , Hemocromatose , Neoplasias Hepáticas , Neoplasias Pancreáticas , Sarcoma , Animais , Adenocarcinoma/veterinária , Ácido Ascórbico , Carcinoma Hepatocelular/veterinária , Quirópteros/metabolismo , Hemocromatose/complicações , Hemocromatose/veterinária , Neoplasias Hepáticas/veterinária , Neoplasias Pancreáticas/veterinária , Estudos Retrospectivos , Sarcoma/veterináriaAssuntos
Hemocromatose , Neoplasias Cutâneas , Humanos , Hemocromatose/genética , Hemocromatose/complicações , Estudos de Casos e Controles , Neoplasias Cutâneas/genética , Neoplasias Cutâneas/epidemiologia , Masculino , Feminino , Pessoa de Meia-Idade , Idoso , Carcinoma Basocelular/epidemiologia , Carcinoma Basocelular/genética , Carcinoma de Células Escamosas/genética , AdultoRESUMO
Background: Iron overload is frequent in patients with chronic liver disease, associated with shorter survival after liver transplantation in patients with hereditary hemochromatosis. Its effect on patients without hereditary hemochromatosis is unclear. The aim of the study was to study the clinical impact of iron overload in patients who underwent liver transplantation at an academic tertiary referral center. Methods: We performed a retrospective cohort study including all patients without hereditary hemochromatosis who underwent liver transplantation from 2015 to 2017 at an academic tertiary referral center in Mexico City. Explant liver biopsies were reprocessed to obtain the histochemical hepatic iron index, considering a score ≥ 0.15 as iron overload. Baseline characteristics were compared between patients with and without iron overload. Survival was estimated using the Kaplan-Meier method, compared with the log-rank test and the Cox proportional hazards model. Results: Of 105 patients included, 45% had iron overload. Viral and metabolic etiologies, alcohol consumption, and obesity were more frequent in patients with iron overload than in those without iron overload (43% vs. 21%, 32% vs. 22%, p = 0.011; 34% vs. 9%, p = 0.001; and 32% vs. 12%, p = 0.013, respectively). Eight patients died within 90 days after liver transplantation (one with iron overload). Complication rate was higher in patients with iron overload versus those without iron overload (223 vs. 93 events/100 personmonths; median time to any complication of 2 vs. 3 days, p = 0.043), without differences in complication type. Fatality rate was lower in patients with iron overload versus those without iron overload (0.7 vs. 4.5 deaths/100 person-months, p = 0.055). Conclusion: Detecting iron overload might identify patients at risk of early complications after liver transplantation. Further studies are required to understand the role of iron overload in survival.
Assuntos
Hemocromatose , Sobrecarga de Ferro , Hepatopatias , Transplante de Fígado , Humanos , Transplante de Fígado/efeitos adversos , Hemocromatose/complicações , Hemocromatose/epidemiologia , Hemocromatose/patologia , Estudos Retrospectivos , Sobrecarga de Ferro/etiologia , Sobrecarga de Ferro/complicações , Hepatopatias/complicações , Hepatopatias/metabolismo , Hepatopatias/patologia , Fígado/metabolismoRESUMO
BACKGROUND AND AIMS: Haemochromatosis is characterized by progressive iron overload affecting the liver and can cause cirrhosis and hepatocellular carcinoma. Most haemochromatosis patients are homozygous for p.C282Y in HFE, but only a minority of individuals with this genotype will develop the disease. The aim was to assess the penetrance of iron overload, fibrosis, hepatocellular carcinoma and life expectancy. METHODS: A total of 8839 individuals from the Austrian region of Tyrol were genotyped for the p.C282Y variant between 1997 and 2021. Demographic, laboratory parameters and causes of death were assessed from health records. Penetrance, survival, and cancer incidence were ascertained from diagnosed cases, insurance- and cancer registry data. Outcomes were compared with a propensity score-matched control population. RESULTS: Median age at diagnosis in 542 p.C282Y homozygous individuals was 47.8 years (64% male). At genotyping, the prevalence of iron overload was 55%. The cumulative penetrance of haemochromatosis defined as the presence of provisional iron overload was 24.2% in males and 10.5% in females aged 60 years or younger. Among p.C282Y homozygotes of the same ages, the cumulative proportion of individuals without fibrosis (FIB-4 score < 1.3) was 92.8% in males and 96.7% in females. Median life expectancy was reduced by 6.8 years in individuals homozygous for p.C282Y when compared with population-matched controls (p = .001). Hepatocellular carcinoma incidence was not significantly higher in p.C282Y homozygotes than in controls matched for age and sex. CONCLUSION: Reduced survival and the observed age-dependent increase in penetrance among p.C282Y homozygotes call for earlier diagnosis of haemochromatosis to prevent complications.
Assuntos
Carcinoma Hepatocelular , Hemocromatose , Sobrecarga de Ferro , Neoplasias Hepáticas , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Hemocromatose/epidemiologia , Hemocromatose/genética , Hemocromatose/complicações , Penetrância , Carcinoma Hepatocelular/epidemiologia , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/complicações , Estudos de Coortes , Incidência , Antígenos de Histocompatibilidade Classe I/genética , Proteína da Hemocromatose/genética , Sobrecarga de Ferro/complicações , Homozigoto , Cirrose Hepática/complicações , Neoplasias Hepáticas/epidemiologia , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/complicações , MutaçãoRESUMO
La hemocromatosis es una enfermedad caracterizada por el excesivo depósito de hierro en múltiples órganos, entre ellos hígado, páncreas, piel y corazón. La infiltración de este último es un importante factor en morbilidad y mortalidad. Presentamos un caso de un paciente pediátrico con insuficiencia cardíaca terminal que ameritó trasplante cardíaco, que resultó sin complicaciones. Posterior a la cirugía, mostró mejoría bioquímica y clínica, lo que influyó positivamente en su calidad de vida y prolongó su supervivencia.
Hemochromatosis is a disease characterized by excess iron stores in multiple organs, including the liver, pancreas, skin, and heart. The infiltration of the heart is an important factor in morbidity and mortality. Here we describe the case of a pediatric patient with end-stage heart failure who required a heart transplantation, with no complications. After the surgery, she showed biochemical and clinical improvement, with a positive impact on her quality of life and a prolonged survival.
Assuntos
Humanos , Feminino , Criança , Transplante de Coração , Sobrecarga de Ferro/complicações , Hemocromatose/complicações , Hemocromatose/diagnóstico , Qualidade de Vida , FígadoRESUMO
Iron accumulation in parenchymal cells results in toxic damage and cell death which can determine a functional organ failure. The prototypical disease is hereditary hemochromatosis (HH). HH has been associated to mutations affecting any of the proteins that regulate iron metabolism. The most common cause of HH is a mutation in the HFE gene [C282Y]. Mutations in the gene for the hormone hepcidin and any of other eight genes that regulate iron biology, including the transferrin receptor 2 (TfR2), hemojuvelin (HJV) and ferroportin (FPN), also cause iron overload and hemochromatosis. Although information is limited, HFE-associated to HH is uncommon in Chile. Evaluation of iron overload in clinical practice should include consideration of co-factors such as alcohol consumption, the presence of virus infection hepatitis C virus and nonalcoholic steatohepatitis, which independently can contribute to iron accumulation. While genetic testing is useful, analysis of liver histology and imaging evaluation of iron overload by MRI are important tools for clinical evaluation. This article reviews current concepts on the clinical diagnosis and management of hepatic iron overload.
La acumulación de hierro en las células parenquimatosas determina la ocurrencia de daño tóxico y muerte celular, lo que puede producir una insuficiencia funcional. La enfermedad prototípica es la hemocromatosis hereditaria (HH). La HH se ha asociado a mutaciones que afectan a cualquiera de las proteínas que regulan el metabolismo del hierro. La causa más común de HH es una mutación en el gen HFE [C282Y]. Mutaciones en el gen de la hormona hepcidina (HAMP) y cualquiera de los 8 genes que regulan su biología, incluyendo el receptor de transferrina 2 (TfR2), hemojuvelina (HJV) y ferroportina(FPN), también causan sobrecarga de hierro y hemocromatosis. Aunque la información es limitada, la HH asociada a HFE es infrecuente en nuestro medio. La evaluación de la sobrecarga de hierro en la práctica clínica debe contemplar la evaluación de otros factores tales como el consumo de alcohol, la presencia de infección por el virus de la hepatitis por virus C y de esteatohepatitis no alcohólica. Si bien el test genético es de utilidad, los análisis de la histología hepática y la evaluación imagenológica de la sobrecarga de hierro mediante resonancia magnética son útiles para la evaluación clínica de la sobrecarga de hierro. El presente artículo revisa conceptos actuales sobre el manejo clínico de la sobrecarga de hierro hepática.
Assuntos
Humanos , Hemocromatose/complicações , Hemocromatose/diagnóstico , Hemocromatose/terapia , Hepatopatias/complicações , Flebotomia , Hemocromatose/classificação , Hemocromatose/etiologia , Peptídeos Catiônicos AntimicrobianosRESUMO
Portadores de talassemia major (TM) permanecem assintomáticos e com funções ventriculares preservadas por longo tempo, porém, duas condições básicas podem ser responsáveis pelo comprometimento da função cardíaca nesse indivíduos, a anemia e a hemocromatose. Recentes avanços na ecocardiografia possibilitaram a utilização dessa técnica para a identificação precoce de disfunção ventricular secundária à hemocromatose. Além disso, esse exame constitui instrumento valioso para o acompanhamento evolutivo de pacientes, permitindo comparações de variáveis estruturais e funcionais cardíacas em diferentes momentos.
Assuntos
Humanos , Ecocardiografia Doppler/métodos , Ecocardiografia Doppler , Hemocromatose/complicações , Hemocromatose/diagnóstico , Talassemia/complicações , Talassemia/diagnóstico , Remodelação VentricularAssuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Hemocromatose/genética , Antígenos de Histocompatibilidade Classe I/genética , Sobrecarga de Ferro/genética , Proteínas de Membrana/genética , Mutação/genética , Biópsia , Ferritinas/análise , Genótipo , Hemocromatose/complicações , Hemocromatose/diagnóstico , Hemocromatose/etiologia , Sobrecarga de Ferro/complicações , Sobrecarga de Ferro/diagnóstico , Fígado/patologia , FenótipoRESUMO
La porfiria cutánea tarda (PCT) es considerada una manifestación extrahepática de la infección por el virusde la hepatitis C (HCV). La frecuencia de esta asociación es variable y no es claro el mecanismo por el cual el virus la desencadena. Se presenta un hombre de 47 años con hepatitis C, genotipo-1b, que durante el tratamiento con peg-interferón alfa-2b más ribavirinasin viremia detectable en las semanas 12, 24 y 48, en la semana 44 consulta por presentar lesiones dermatológicasfotosensibles. Con el diagnóstico presuntivo de PCT se realizó biopsia cutánea y el dosaje de porfirinasurinarias fue 4185 ug/24hs (vn: < 250). El análisis cromatográfico reveló el típico patrón de PCT, confirmando el diagnóstico. El gen HFE de la hemocromatosis mostró mutaciones de carácter heterocigoto (H63D y C282Y), asociación frecuente en los pacientescon sobrecarga de hierro y PCT. El tratamiento antiviral de la infección por HCV puede mejorar las manifestacionesde la PCT. La ocurrencia de novo de éstafue reportada recientemente durante el tratamiento de la hepatitis C crónica con interferón y ribavirina pero no hay casos relatados de aparición tardía de PCT enpacientes HCV con viremia no detectable. La presencia de la mutación del gen HFE y la posibilidad de unaumento de oferta de hierro por la acción hemolítica de la ribavirina podrían explicar un exceso de hierrocapaz de desencadenar la crisis de PCT. Tampoco sonconcluyentes los estudios con respecto al aumento o no de la concentración de hierro en hígado en pacientes con anemia que reciben ribavirina.
Porphyria cutanea tarda (PCT) is considered an extra-hepatic manifestation of HCV infection. The frequency of this association varies according to different authors and the mechanism by which the virus can trigger this disease is not yet clear. We present a 47-year-old-man with chronic hepatitis C genotype 1b who, during the treatment with peg-interferón alfa 2b plus ribavirina, with no detectable viremia at weeks 12th, 24th, and 48th, developed dermatological photosensitive lesions at week 44th. With a presumptive diagnosis of PCT a cutaneous/skin biopsy was performed as well as a porphyrin dosage with urine porphyirins of 4185 microg/24 hs (nv<250). The chromatographic analysis revealed the typical PCT pattern thus confirming the diagnosis. The hemochromatosis HFE gen evaluation showed heterozigotus character mutations (H63D and C282Y) a frequent association in patients with iron overload and PCT. The antiviral treatment of the HCV infection can improve the clinical-humoral manifestations of PCT. The novo occurrence of PCT was recently reported during chronic hepatitis C treatment with interferón and ribavirin, but no cases of late appearance of PCT in patients with no detectable viremia were reported. The mutation of the gen HFE in our patient and the hemolysis caused by ribavirin can be related to the development of the disease, but the iron overload because of ribavirin use is also controversial. This is another example of the complexity of this association.
Assuntos
Humanos , Masculino , Pessoa de Meia-Idade , Interferon-alfa , Antivirais/uso terapêutico , Hepatite C Crônica/tratamento farmacológico , Porfiria Cutânea Tardia/tratamento farmacológico , Ribavirina/uso terapêutico , Hemocromatose/complicações , Hepatite C Crônica/complicações , Porfiria Cutânea Tardia/genética , Porfiria Cutânea Tardia/virologiaRESUMO
Epidemiological studies indicate a positive relation between iron status and coronary artery disease (CAD) risk The HFE C282Y allele is associated with increased iron status and higher CAD risk. We investigated whether HFE C282Ymight be a CAD risk factor in Curaçao in a case-control study design. The patient group comprised 42 men and 10 women. Fifty-four men and 30 women without history of CAD served as age and gender matched controls. HFE C282Y genotypes were established using sequence-specific priming polymerase chain reaction. None of the investigated subjects were homozygous for HFE C282Y, whereas 5/52 (9.6) CAD patients and 1/84 controls (1.2) were heterozygous for HFE C282Y (p = 0.03). The HFE C282Y mutation was 8.8 fold (95 CI 1.001, 77.8; p = 0.049) more prevalent in CAD patients than in controls. The HFE C282Y allele frequency in Curaçao is higher than that of African populations, but comparable with that of Jamaica. We conclude that Curaçao CAD patients have somewhat higher frequency of HFE C282Y heterozygosity than controls, and that the HFE C282Y allele frequency in the Curaçao population is higher than might be expected in persons of African descent. The consequences of HFE C282Y heterozygosity as CAD risk factor are as yet uncertain, since there is no proof that iron lowering reduces CAD risk
Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Antígenos de Histocompatibilidade Classe I/genética , Doença das Coronárias/genética , Mutação , Proteínas de Membrana/genética , Alelos , Antilhas Holandesas/epidemiologia , Doença das Coronárias/epidemiologia , Triagem de Portadores Genéticos , Estudos de Casos e Controles , Fatores de Risco , Hemocromatose/complicações , Hemocromatose/genética , Prevalência , Reação em Cadeia da PolimeraseAssuntos
Humanos , Masculino , Adulto , Hemocromatose/complicações , Hemocromatose/diagnóstico , Hemocromatose/etiologia , Hemocromatose/genética , Hemocromatose/história , Hemocromatose/prevenção & controle , Hemocromatose/terapia , Sobrecarga de Ferro/diagnóstico , Sobrecarga de Ferro/etiologia , Sobrecarga de Ferro/terapia , Análise Química do Sangue , Biópsia , Diagnóstico Diferencial , Diagnóstico Precoce , Genes MHC Classe I , Hepatopatias Alcoólicas , Ferro/metabolismo , Fígado/patologia , Marcadores Genéticos , Porfiria Cutânea TardiaRESUMO
Hemocromatose hereditária é o termo usado para identificar uma doença ligada ao complexo maior de histocompatibilidade humana, de herança genética, onde há um inapropriado aumento da absorção intestinal de ferro. Cirrose hepática, diabetes, artrite e cardiopatia são achados frequentes em pacientes com a doença estabelecida. Os autores relatam caso de paciente com essa enfermidade e fazem uma revisão na literatura especializada acerca de sua fisiopatologia, métodos diagnósticos e terapêutica
Assuntos
Humanos , Masculino , Adulto , Hemocromatose/fisiopatologia , Sobrecarga de Ferro/etiologia , Hemocromatose/complicações , Hemocromatose/diagnóstico , Hemocromatose/terapiaRESUMO
Säo demonstradas alteraçöes transitórias bipalidais caracterizadas por hiperintensidade na sequência T1 da ressonância nuclear magnética, que ocorreram em um paciente com degeneraçäo hepatocerebral adquirida provocada por hemocromatose. Em funçäo de acrescentar-se a este sinal a visibilizaçäo de imagem de hiperintensidade bitalâmica na sequência T2, discute-se a hipótese destes sinais serem unicamente secundários â degeneraçäo hepatocerebral ou, ainda, se teriam sido também originados pela própria hemocromatose.